U.S. Pharma Stock News

NYSE:TUYA
NYSE:TUYASoftware

Is Tuya’s (TUYA) Earnings Preview Quietly Reframing Its Long-Term Profitability Narrative?

Tuya recently announced it will release its quarterly earnings on March 2, 2026, with analysts expecting earnings per share of US$0.03. Investor attention is centering on whether Tuya’s earnings update will align with its track record of revenue growth and solid profitability metrics. We’ll now examine how anticipation around Tuya potentially outperforming current EPS expectations could influence the company’s broader investment narrative. Capitalize on the AI infrastructure supercycle with...
NYSE:ORI
NYSE:ORIInsurance

Does Old Republic’s Higher 2026 Dividend Payout Signal a Shift in Capital Priorities for ORI?

Old Republic International Corporation recently declared a regular quarterly cash dividend of US$0.315 per share, payable on March 19, 2026 to shareholders of record on March 9, 2026. This raises the full-year cash dividend to US$1.26 per share, an 8.6% increase over 2025 that underlines management’s confidence in the company’s cash generation. Next, we’ll examine how this higher regular dividend, following a steady earnings report, affects Old Republic International’s investment...
NasdaqGS:SNDK
NasdaqGS:SNDKTech

Sandisk Ties High Bandwidth Flash Push To AI And Valuation Story

Sandisk (NasdaqGS:SNDK) and SK hynix have launched a global standardization push for next generation High Bandwidth Flash, or HBF, memory technology. The effort focuses on creating a shared framework for HBF aimed at AI inference workloads across data centers and other AI driven infrastructure. The initiative targets a new memory layer that seeks to combine high performance and high capacity while addressing power efficiency constraints. For you as an investor, this move sits at the...
NYSE:REXR
NYSE:REXRIndustrial REITs

Is Rexford Industrial Realty (REXR) Fairly Priced After Recent Share Price Weakness

If you are wondering whether Rexford Industrial Realty is attractively priced today, the key question is how its current share price lines up with its underlying fundamentals. The stock last closed at US$37.88, with returns of 2.0% over the past week, a 3.9% decline over the past month, and a 2.9% decline both year to date and over the past year, while the three and five year returns sit at 30.3% and 5.8% declines respectively. Recent attention on Rexford Industrial Realty has centered on...
NYSE:KEY
NYSE:KEYBanks

Is KeyCorp (KEY) Pricing Reflect Recent Regional Bank Sector Uncertainty Accurately

If you are wondering whether KeyCorp's current share price reflects its underlying value, you are not alone. This article is built to help you make sense of that question in a clear, practical way. Over recent periods, the stock has shown mixed returns: about 0.3% over the last week, 1.9% over the past month, 4.2% year to date, 34.9% over 1 year, 42.4% over 3 years and 36.1% over 5 years. These figures may lead some investors to reassess both its potential and its risks. Recent news around...
NasdaqGS:VSAT
NasdaqGS:VSATCommunications

Should Viasat’s Return to Profitability and Bandwidth Expansion Require Action From Viasat (VSAT) Investors?

Viasat recently returned to profitability in its fiscal Q3 2026 with US$25.0 million in net income, supported by a US$420.0 million payment from Ligado, while advancing its Inmarsat acquisition and expanding satellite capacity with the ViaSat-3 F2 program. Alongside new antenna deployments with Astralintu and connected-vehicle voice calling trials, these developments highlight Viasat’s push to deepen its role in global satellite infrastructure and services. We’ll now explore how Viasat’s...
NYSE:ET
NYSE:ETOil and Gas

A Look At Energy Transfer (ET) Valuation As Recent Momentum Draws Investor Attention

Why Energy Transfer is on investors’ radar today Energy Transfer (ET) is back in focus after recent trading action, with the units last closing at $18.69. You might be weighing how its income profile and long record of pipeline assets fit your portfolio. See our latest analysis for Energy Transfer. The unit price has shown steady upward momentum recently, with a 30 day share price return of 4.12% and a 90 day share price return of 11.85%. The 5 year total shareholder return of 244.46% points...
NYSE:NOW
NYSE:NOWSoftware

ServiceNow AI Push Tests Workflow Ambitions As Moveworks Wins FedRAMP

ServiceNow (NYSE:NOW) has launched Autonomous Workforce and EmployeeWorks, two AI powered platforms aimed at automating complex enterprise workflows. The company is integrating Moveworks technology to bring advanced conversational AI into its ecosystem. Moveworks has received FedRAMP Moderate Authorization, allowing its cloud services to be used in certain U.S. federal government environments. For investors watching NYSE:NOW, these launches come at a time when the stock is trading at...
NYSE:GENI
NYSE:GENIHospitality

Is Genius Sports (GENI) Pricing Reflect Its DCF Upside And Sports Data Deal Momentum

If you are wondering whether Genius Sports at around US$6.39 is a bargain or just fairly priced, you are not alone. The stock has had a mixed run, with a 0.3% decline over the last week, a 32.8% decline over the last month, a 40.7% decline year to date, a 24.1% decline over the last year, but a 37.7% return over three years. Recent news around Genius Sports has focused on its role as a data and technology provider to sports leagues and betting operators, along with ongoing attention on how...
NYSE:GPGI
NYSE:GPGITech

What GPGI (GPGI)'s Husky Accounting Allegations And Executive Exits Mean For Shareholders

Earlier in February 2026, Jehoshaphat Research disclosed a short position in GPGI, alleging that the company overstated Husky Technologies’ financial performance and highlighting the unexpected resignations of Husky’s CEO and CFO without immediate successors. This combination of accounting concerns and abrupt leadership changes at the company’s largest earnings contributor has raised fresh questions about GPGI’s post-merger integration and reporting quality. We’ll now examine how these...
NYSE:C
NYSE:CBanks

Is It Too Late To Consider Citigroup (C) After 51% One Year Share Price Jump?

If you are wondering whether Citigroup still offers value at its current share price, or if most of the potential upside has already been reflected, this article breaks down what the numbers are really saying about the stock. Citigroup's share price recently closed at US$116.19, with returns of 0.6% over 7 days, 1.2% over 30 days, a 2.1% decline year to date and 51.1% over the past year, plus 150.9% over 3 years and 98.3% over 5 years for longer term context. Recent headlines around...
NasdaqGS:BEAM
NasdaqGS:BEAMBiotechs

Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch

Beam Therapeutics (BEAM) caught investors attention after a Q4 earnings surprise, a new US$500 million credit facility to back commercialization and pipeline work, and the launch of its PKU program BEAM-304. See our latest analysis for Beam Therapeutics. The Q4 earnings surprise, new PKU program, and US$500 million credit facility have arrived against a backdrop where the latest share price of US$28.92 sits on a 90 day share price return of 14.17%, a year to date share price gain of 6.56%,...
NYSE:FRO
NYSE:FROOil and Gas

Frontline (NYSE:FRO) Valuation In Focus After Strong Q4 Revenue And Earnings Performance

Q4 earnings highlight a strong finish to 2025 Frontline (FRO) just released its fourth quarter and full year 2025 results, with Q4 revenue of US$624.51 million and net income of US$227.93 million standing out against softer full year figures. The company reported Q4 basic and diluted earnings per share from continuing operations of US$1.02, compared with US$0.30 a year earlier. Full year EPS from continuing operations came in at US$1.70 versus US$2.23 in 2024. See our latest analysis for...
NYSE:PWR
NYSE:PWRConstruction

Quanta Services Raises Growth Outlook As Infrastructure Backlog And Acquisitions Build

Quanta Services (NYSE:PWR) reported quarterly results that exceeded expectations and highlighted strong operational performance. The company completed eight acquisitions in 2025 that expand its footprint across key infrastructure markets. Management outlined double digit growth projections for 2026 and pointed to a record backlog and project pipeline. Quanta is positioning itself around large scale infrastructure shifts, including renewable energy projects and broadband and 5G...
NYSE:AVTR
NYSE:AVTRLife Sciences

Assessing Avantor (AVTR) Valuation After Recent Share Price Weakness And Perceived Undervaluation

Avantor stock moves after recent performance shift Avantor (AVTR) has come into focus after a recent stretch of weaker share performance, with the stock showing negative returns over the past week, month and past 3 months, as well as over the past year. See our latest analysis for Avantor. At a share price of US$9.01, Avantor’s recent momentum has been weak, with a 30 day share price return of 22.66% and a 1 year total shareholder return of 45.36% pointing to sustained pressure on the...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit Anthropic AI Deal Tests Valuation Gap And Growth Expectations

Intuit and Anthropic have entered a multi year partnership to build custom, secure AI agents for mid market businesses and consumers. The agreement will embed Intuit’s tax, finance, and accounting capabilities directly into Anthropic’s Claude Agent SDK and AI environments. The collaboration aims to support operational automation, financial insights for businesses, and personal finance assistance for individuals. Intuit, listed as NasdaqGS:INTU, is moving deeper into AI by putting its...
NYSE:PRU
NYSE:PRUInsurance

What Prudential Financial (PRU)'s New Bond Issuance Amid Analyst Downgrades Means For Shareholders

In February 2026, Prudential Financial announced and then completed fixed-income offerings, including 4.100% senior unsecured notes due 2031 and 4.650% callable senior unsecured notes due 2036, both issued at 100% price with discounts to the offering price and fixed coupons. These bond deals, alongside recent analyst rating cuts on Prudential Financial, highlight how the company is simultaneously accessing debt markets while facing fresh external scrutiny of its outlook. With multiple...
NYSE:TOL
NYSE:TOLConsumer Durables

Is It Too Late To Consider Toll Brothers (TOL) After Its Strong Multi Year Rally?

If you are wondering whether Toll Brothers is still reasonably priced after its strong run, this article will walk through what the current share price might be implying about value. The stock most recently closed at US$158.65, with a 1% decline over the last 7 days, a 10.9% return over 30 days, a 17.0% return year to date, a 44.6% return over 1 year, and a 175.4% return over 3 years, while the 5 year return is very large. Recent news coverage has focused on Toll Brothers as a key name in US...
NasdaqGS:AVO
NasdaqGS:AVOFood

Assessing Mission Produce (AVO) Valuation After Strong Results And A Mixed Profitability Outlook

Mission Produce (AVO) is back in focus after strong quarterly results highlighted benefits from its vertically integrated model in sourcing and distribution, even as projected revenue declines and low gross margins leave analysts cautious. See our latest analysis for Mission Produce. At a share price of $14.10, Mission Produce has cooled off slightly in the last week, with a 7 day share price return of a 4.73% decline. However, the 90 day share price return of 17.30% and the 1 year total...
NasdaqGM:VWAV
NasdaqGM:VWAVAerospace & Defense

A Look At VisionWave Holdings (VWAV) Valuation After Interceptor Drone MOU In Germany And Israel

VisionWave Holdings (VWAV) has drawn fresh attention after signing a Memorandum of Understanding with partners in Germany and Israel to explore non explosive interceptor drone systems tailored to German Bundeswehr and NATO operational requirements. See our latest analysis for VisionWave Holdings. At a share price of $7.96, VisionWave’s recent MOU, AI radar concept work, governance changes, mining software program, and wider funding activity come against a backdrop of a 30 day share price...
NYSE:HTH
NYSE:HTHBanks

The Bull Case For Hilltop Holdings (HTH) Could Change Following Mounting Profitability Pressures And Efficiency Concerns

Recent commentary on Hilltop Holdings highlights that over the past five years its net interest income has been flat, earnings per share have fallen about 15% a year, and analysts now expect its efficiency ratio to deteriorate, pointing to mounting profitability pressures. An important implication is that Hilltop may be struggling to adjust its fixed cost base and operations to softer demand, raising questions about how effectively it can respond to industry headwinds. Now we’ll assess how...
NYSE:CQP
NYSE:CQPOil and Gas

How Investors May Respond To Cheniere Energy Partners (CQP) Earnings Beat, Higher Payout Guidance And Rating Upgrade

Cheniere Energy Partners, L.P. recently reported past fourth-quarter and full-year 2025 results showing higher revenue and net income year over year, while also issuing 2026 distribution guidance of US$3.10–US$3.40 per common unit and maintaining a US$3.10 base distribution. Alongside a very large earnings beat versus analyst expectations, the partnership highlighted its Sabine Pass expansion plans and an S&P rating upgrade to BBB+ with a stable outlook, underscoring its evolving position in...
NasdaqGS:INTA
NasdaqGS:INTASoftware

Intapp’s Celeste AI And Partnerships Test Valuation Gap In Regulated Markets

Intapp (NasdaqGS:INTA) has launched Celeste, a purpose-built agentic AI platform focused on regulated professional services. The company also announced new partnerships with Anthropic to integrate Claude and with Harvey to embed Intapp Walls for ethical compliance in enterprise AI deployments. These moves aim to address compliance-heavy workflows and data governance needs for firms in legal, accounting, and investment banking. For investors watching enterprise software, Intapp sits at the...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex Broadens Growth Story With Gene Editing And Non Opioid Pain Therapies

Vertex Pharmaceuticals (NasdaqGS:VRTX) has expanded beyond cystic fibrosis with recent approvals for Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia. The company also received approval for Journavx, a non-opioid acute pain medication, widening its presence in serious disease areas. These new therapies mark a shift from reliance on a single therapy area to a broader portfolio in gene-editing and pain management. For investors tracking Vertex Pharmaceuticals, the...